AU2008210434C8 - Stabilized p53 peptides and uses thereof - Google Patents
Stabilized p53 peptides and uses thereof Download PDFInfo
- Publication number
- AU2008210434C8 AU2008210434C8 AU2008210434A AU2008210434A AU2008210434C8 AU 2008210434 C8 AU2008210434 C8 AU 2008210434C8 AU 2008210434 A AU2008210434 A AU 2008210434A AU 2008210434 A AU2008210434 A AU 2008210434A AU 2008210434 C8 AU2008210434 C8 AU 2008210434C8
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- modified polypeptide
- leu
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013231104A AU2013231104B2 (en) | 2007-01-31 | 2013-09-20 | Stabilized p53 peptides and uses thereof |
| AU2016210709A AU2016210709B2 (en) | 2007-01-31 | 2016-08-04 | Stabilized p53 peptides and uses thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88752607P | 2007-01-31 | 2007-01-31 | |
| US60/887,526 | 2007-01-31 | ||
| PCT/US2008/052580 WO2008095063A1 (en) | 2007-01-31 | 2008-01-31 | Stabilized p53 peptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013231104A Division AU2013231104B2 (en) | 2007-01-31 | 2013-09-20 | Stabilized p53 peptides and uses thereof |
Publications (6)
| Publication Number | Publication Date |
|---|---|
| AU2008210434A1 AU2008210434A1 (en) | 2008-08-07 |
| AU2008210434A8 AU2008210434A8 (en) | 2009-12-17 |
| AU2008210434B2 AU2008210434B2 (en) | 2013-06-20 |
| AU2008210434C1 AU2008210434C1 (en) | 2013-11-14 |
| AU2008210434C9 AU2008210434C9 (en) | 2013-12-12 |
| AU2008210434C8 true AU2008210434C8 (en) | 2014-03-27 |
Family
ID=39674492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008210434A Ceased AU2008210434C8 (en) | 2007-01-31 | 2008-01-31 | Stabilized p53 peptides and uses thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8889632B2 (enExample) |
| EP (2) | EP2118123B1 (enExample) |
| JP (3) | JP5649825B2 (enExample) |
| AU (1) | AU2008210434C8 (enExample) |
| CA (2) | CA2939778C (enExample) |
| DK (1) | DK2118123T3 (enExample) |
| ES (1) | ES2558928T3 (enExample) |
| PL (1) | PL2118123T3 (enExample) |
| PT (1) | PT2118123E (enExample) |
| WO (1) | WO2008095063A1 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| WO2005044839A2 (en) | 2003-11-05 | 2005-05-19 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
| US8940864B2 (en) | 2006-10-05 | 2015-01-27 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| US8937154B2 (en) | 2006-10-05 | 2015-01-20 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| US7981998B2 (en) * | 2006-12-14 | 2011-07-19 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
| BRPI0720306A2 (pt) * | 2006-12-14 | 2014-02-04 | Aileron Therapeutics Inc | Sistemas de macrociclização da bis-sufidrila |
| PL2118123T3 (pl) | 2007-01-31 | 2016-06-30 | Dana Farber Cancer Inst Inc | Stabilizowane peptydy p53 i ich zastosowania |
| CA2678941C (en) * | 2007-02-23 | 2018-11-27 | Aileron Therapeutics, Inc. | Triazole macrocycle systems |
| JP5631201B2 (ja) * | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ステッチングされたポリペプチド |
| CA2725227A1 (en) | 2008-05-06 | 2009-11-12 | Asim Kumar Debnath | Antiviral cell penetrating peptides |
| US20110144306A1 (en) * | 2008-07-23 | 2011-06-16 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
| CN104961795A (zh) * | 2008-09-22 | 2015-10-07 | 爱勒让治疗公司 | 用于制备纯化的多肽组合物的方法 |
| CN102482336B (zh) | 2008-09-22 | 2015-05-06 | 爱勒让治疗公司 | 拟肽大环化合物 |
| CA2743177A1 (en) | 2008-11-24 | 2010-05-27 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with improved properties |
| EP2358748B1 (en) * | 2008-12-09 | 2016-07-06 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for specific modulation of mcl-1 |
| AU2010204648B2 (en) | 2009-01-14 | 2016-09-01 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| BR112012000867A2 (pt) | 2009-07-13 | 2019-09-24 | Harvard College | "polipeptídeos bifuncional costurado e uso do mesmo" |
| JP2013505300A (ja) | 2009-09-22 | 2013-02-14 | エルロン・セラピューティクス・インコーポレイテッド | ペプチド模倣大環状分子 |
| KR102104762B1 (ko) | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| WO2012040459A2 (en) * | 2010-09-22 | 2012-03-29 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
| JP2014502152A (ja) | 2010-11-12 | 2014-01-30 | ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド | 癌の治療及び診断 |
| US9029332B2 (en) | 2010-12-15 | 2015-05-12 | The Research Foundation For The State University Of New York | Cross-linked peptides and proteins, methods of making same, and uses thereof |
| WO2012174423A1 (en) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Stabilized polypeptides as regulators of rab gtpase function |
| EP2768518A4 (en) | 2011-10-18 | 2015-05-27 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| HK1208039A1 (en) | 2011-12-29 | 2016-02-19 | Dana-Farber Cancer Institute, Inc. | Stabilized antiviral fusion helices |
| CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| RU2642299C2 (ru) * | 2012-02-15 | 2018-01-24 | Эйлерон Терапьютикс, Инк. | P53 пептидомиметические макроциклы |
| RS61957B1 (sr) | 2012-09-26 | 2021-07-30 | Harvard College | Uvezani peptidi blokirani prolinom i njihove upotrebe |
| WO2014055564A1 (en) | 2012-10-01 | 2014-04-10 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
| KR20150131244A (ko) | 2013-03-13 | 2015-11-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스테이플드 및 스티치드 폴리펩티드 및 그의 용도 |
| WO2014144768A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Bh4 stabilized peptides and uses thereof |
| BR112015031277A2 (pt) | 2013-06-14 | 2017-09-19 | Harvard College | Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos |
| WO2015158810A1 (en) | 2014-04-17 | 2015-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polypeptides and uses thereof for reducing cd95-mediated cell motility |
| EP3145523A4 (en) | 2014-05-21 | 2018-02-21 | President and Fellows of Harvard College | Ras inhibitory peptides and uses thereof |
| EP3197478A4 (en) | 2014-09-24 | 2018-05-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN107106642B (zh) | 2014-09-24 | 2021-02-26 | 艾瑞朗医疗公司 | 拟肽大环化合物及其制剂 |
| EP3245301B1 (en) | 2015-01-12 | 2020-11-11 | Eutropics Pharmaceuticals, Inc. | Context dependent diagnostics test for guiding cancer treatment |
| US11142554B2 (en) | 2015-03-18 | 2021-10-12 | Massachusetts Institute Of Technology | Selective Mcl-1 binding peptides |
| JP2018516844A (ja) | 2015-03-20 | 2018-06-28 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその使用 |
| US11155577B2 (en) | 2015-06-22 | 2021-10-26 | University Of Utah Research Foundation | Thiol-ene based peptide stapling and uses thereof |
| US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| CA2989311A1 (en) * | 2015-07-02 | 2017-01-05 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides |
| EP3341008B1 (en) | 2015-08-28 | 2026-04-15 | Dana-Farber Cancer Institute, Inc. | Peptides binding to bfl-1 |
| US20190002506A1 (en) | 2015-08-28 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Stabilized peptides for covalent binding to target protein |
| EP3347372A4 (en) | 2015-09-10 | 2019-09-04 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 |
| CN109069578A (zh) | 2016-02-29 | 2018-12-21 | 达纳-法伯癌症研究所股份有限公司 | 用于治疗感染的钉合的细胞内靶向抗微生物肽 |
| US11034720B2 (en) | 2016-07-17 | 2021-06-15 | University Of Utah Research Foundation | Thiol-yne based peptide stapling and uses thereof |
| KR102003904B1 (ko) * | 2016-08-17 | 2019-07-25 | 연세대학교 산학협력단 | 안정화된 알파-헬릭스 이차 구조를 갖는 펩타이드-고분자 결합체 제조방법 및 이를 이용해 제조된 펩타이드-고분자 결합체 |
| EP3502669B1 (en) | 2016-08-18 | 2021-10-20 | Horiba, Ltd. | Antibody analyzer, antibody analysis method, and associated computer readable medium |
| AU2017315447B2 (en) | 2016-08-26 | 2023-04-27 | Dana-Farber Cancer Institute, Inc. | Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss |
| EP3551213A4 (en) | 2016-12-07 | 2020-11-04 | The University of Chicago | FOX3 INHIBITION COMPOSITIONS AND METHODS |
| WO2018112226A1 (en) | 2016-12-14 | 2018-06-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sharpin-based polypeptides and their uses |
| CN110891588A (zh) * | 2017-05-11 | 2020-03-17 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
| JP7305614B2 (ja) | 2017-07-19 | 2023-07-10 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド |
| EA202090513A1 (ru) | 2017-09-07 | 2020-08-24 | Фог Фармасьютикалз, Инк. | Агенты, модулирующие функции бета-катенина, и связанные способы |
| AU2018383633B2 (en) | 2017-12-15 | 2024-05-16 | Dana-Farber Cancer Institute, Inc. | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides |
| WO2019118893A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Stabilized peptide-mediated targeted protein degradation |
| WO2019157131A1 (en) | 2018-02-07 | 2019-08-15 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
| US20200408746A1 (en) * | 2018-03-14 | 2020-12-31 | Dana-Farber Cancer Institute, Inc. | Stabilized Peptides for Biomarker Detection |
| WO2020023502A1 (en) | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| BR112021003113A2 (pt) | 2018-08-20 | 2021-05-11 | Fog Pharmaceuticals, Inc. | coleções de peptídeos, agentes de peptídeos e métodos de uso dos mesmos |
| EP4600411A3 (en) | 2019-04-09 | 2025-09-10 | The University of Chicago | Versatile peptide and protein macrocyclization and multimerization with diels-alder cycloadditions |
| EP3962933A1 (en) | 2019-04-18 | 2022-03-09 | Dana-Farber Cancer Institute, Inc. | Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides |
| EP3986438B1 (en) * | 2019-06-21 | 2025-04-16 | Merck Sharp & Dohme LLC | P53 activator peptidomimetic macrocycles |
| EP4142766A2 (en) * | 2020-04-27 | 2023-03-08 | Dana Farber Cancer Institute, Inc. | Structurally-stabilized and hdmx-selective p53 peptides and uses thereof |
| AU2021360898A1 (en) | 2020-10-14 | 2023-03-23 | Dana-Farber Cancer Institute, Inc. | Chimeric conjugates for degradation of viral and host proteins and methods of use |
| WO2026024936A2 (en) | 2024-07-25 | 2026-01-29 | Dana-Farber Cancer Institute, Inc. | Bh4 domain peptides and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005044839A2 (en) * | 2003-11-05 | 2005-05-19 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
Family Cites Families (478)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6000A (en) * | 1849-01-02 | Abunah s | ||
| US4000259A (en) | 1975-06-16 | 1976-12-28 | American Home Products Corporation | Cyclic dodecapeptide analogs of somatostatin and intermediates |
| US4438270A (en) | 1977-07-11 | 1984-03-20 | Merrell Toraude Et Compagnie | α-Halomethyl derivatives of α-amino acids |
| US4191754A (en) | 1979-02-28 | 1980-03-04 | Merck & Co., Inc. | Bicyclic somatostatin analogs |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| AU550730B2 (en) | 1982-03-09 | 1986-04-10 | Commonwealth Of Australia, The | Automated metal detection |
| US4728726A (en) | 1982-10-04 | 1988-03-01 | The Salk Institute For Biological Studies | GRF analogs IIIb |
| US4518586A (en) | 1983-01-13 | 1985-05-21 | The Salk Institute For Biological Studies | GRF Analogs III |
| US5416073A (en) | 1983-08-10 | 1995-05-16 | The Adminstrators Of The Tulane Educational Fund | Growth hormone-releasing peptides and method of treating animals, therewith |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5036045A (en) | 1985-09-12 | 1991-07-30 | The University Of Virginia Alumni Patents Foundation | Method for increasing growth hormone secretion |
| US4730006A (en) | 1986-01-27 | 1988-03-08 | Merrell Dow Pharmaceuticals Inc. | Derivatives of 2,6-diamino-3-haloheptanedioic acid |
| US4880778A (en) | 1986-05-12 | 1989-11-14 | Eastman Kodak Company | Combinations having synergistic growth hormone releasing activity and methods for use thereof |
| HU906341D0 (en) | 1986-10-13 | 1991-04-29 | Sandoz Ag | Process for producing peptonic derivatives modified with sugar and pharmaceutical preparatives containing these compounds as active substance |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US5112808A (en) | 1987-05-11 | 1992-05-12 | American Cyanamid Company | Alkylated hormone-releasing peptides and method of treatig mammals therewith |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5877277A (en) | 1987-09-24 | 1999-03-02 | Biomeasure, Inc. | Octapeptide bombesin analogs |
| US5453418A (en) | 1988-03-07 | 1995-09-26 | Eli Lilly And Company | Ractopamine and growth hormone combinations |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| WO1989009233A1 (en) | 1988-03-24 | 1989-10-05 | Terrapin Technologies, Inc. | Molecular sticks for controlling protein conformation |
| US5094951A (en) | 1988-06-21 | 1992-03-10 | Chiron Corporation | Production of glucose oxidase in recombinant systems |
| US5043322A (en) | 1988-07-22 | 1991-08-27 | The Salk Institute For Biological Studies | Cyclic GRF analogs |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5384309A (en) | 1989-07-17 | 1995-01-24 | Genentech, Inc. | Cyclized peptides and their use as platelet aggregation inhibitors |
| US5120859A (en) | 1989-09-22 | 1992-06-09 | Genentech, Inc. | Chimeric amino acid analogues |
| US5650133A (en) | 1990-01-19 | 1997-07-22 | Nycomed Salutar | Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality |
| US5712418A (en) | 1989-10-23 | 1998-01-27 | Research Corporation Technologies, Inc. | Synthesis and use of amino acid fluorides as peptide coupling reagents |
| US5169932A (en) | 1989-10-30 | 1992-12-08 | The Salk Institute For Biological Studies | Gnrh analogs |
| US5580957A (en) | 1989-10-30 | 1996-12-03 | The Salk Institute For Biological Studies | GnRH analogs |
| US5296468A (en) | 1989-10-30 | 1994-03-22 | The Salk Institute For Biological Studies | GnRH analogs |
| US5352796A (en) | 1989-10-30 | 1994-10-04 | The Salk Institute For Biological Studies | Amino acids useful in making GnRH analogs |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5245009A (en) | 1990-03-23 | 1993-09-14 | The Salk Institute For Biological Studies | CRF antagonists |
| CA2047042A1 (en) | 1990-07-19 | 1992-01-20 | John Hannah | Cyclic hiv principal neutralizing determinant peptides |
| US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
| US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| SK32693A3 (en) | 1990-10-11 | 1993-09-09 | Boehringer Ingelheim Kg | Cyclopeptides, a method of preparing them and their use as drugs |
| DE69118826T2 (de) | 1990-11-27 | 1996-11-14 | Fuji Photo Film Co Ltd | Propenamidderivate, deren Polymere, Copolymere und deren Verwendung |
| US5124454A (en) * | 1990-11-30 | 1992-06-23 | Minnesota Mining And Manufacturing Company | Polycyclic diamines and method of preparation |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| CA2103577A1 (en) | 1991-02-07 | 1992-08-08 | Michael Kahn | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| US5744450A (en) | 1991-03-14 | 1998-04-28 | The Salk Institute For Biological Studies | GnRH analogs |
| EP0525838A3 (en) | 1991-04-09 | 1993-02-10 | F. Hoffmann-La Roche Ag | Growth hormone releasing factor analogs |
| US5262519A (en) | 1991-05-15 | 1993-11-16 | The Salk Institute For Biological Studies | GRF analogs XI |
| US5364851A (en) | 1991-06-14 | 1994-11-15 | International Synthecon, Llc | Conformationally restricted biologically active peptides, methods for their production and uses thereof |
| CA2072249C (en) | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| GB9114949D0 (en) | 1991-07-11 | 1991-08-28 | Smithkline Beecham Plc | Novel compounds |
| ATE155486T1 (de) | 1991-08-13 | 1997-08-15 | Takeda Chemical Industries Ltd | Zyklische peptide und ihre verwendung |
| US7517644B1 (en) | 1991-08-23 | 2009-04-14 | Larry J. Smith | Method and compositions for cellular reprogramming |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| IL103252A (en) | 1991-09-30 | 1997-03-18 | Du Pont Merck Pharma | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| EP0552417B1 (en) | 1991-11-19 | 1999-07-07 | Takeda Chemical Industries, Ltd. | Cyclic peptides and use thereof |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| EP1253156A3 (en) | 1992-04-03 | 2004-01-07 | California Institute Of Technology | High activity ruthenium or osmium metal carbene complexes for olefin metathesis reactions and synthesis and application thereof |
| US5411860A (en) | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
| ES2139012T3 (es) | 1992-05-26 | 2000-02-01 | Univ Leiden | Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana. |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE69332377T2 (de) | 1992-07-13 | 2003-07-03 | Bionebraska, Inc. | Verfahren zur modifizierung rekombinanter polypeptide |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| US5371070A (en) | 1992-11-09 | 1994-12-06 | The Salk Institute For Biological Studies | Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins |
| MX9401351A (es) | 1993-02-22 | 1994-08-31 | Alza Corp | Composiciones para suministro oral para agentes activos. |
| FI954556A0 (fi) | 1993-03-29 | 1995-09-26 | Du Pont Merck Pharma | Syklisiä yhdisteitä, jotka ovat käyttökelpoisia verihiutaleen glykoproteiinin IIb/IIIa inhibiittoreina |
| US5643957A (en) | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| AU6770794A (en) | 1993-04-23 | 1994-11-21 | Herbert J. Evans | Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site |
| US5446128A (en) | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
| HU224350B1 (hu) | 1993-08-09 | 2005-08-29 | Société de Conseils de Recherches et d'ApplicationScientifiques, S.A.S. Á | Gyógyhatású peptidszármazékok |
| US5622852A (en) | 1994-10-31 | 1997-04-22 | Washington University | Bcl-x/Bcl-2 associated cell death regulator |
| US5536814A (en) | 1993-09-27 | 1996-07-16 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| WO1995014777A1 (en) | 1993-11-22 | 1995-06-01 | Onyx Pharmaceuticals | p53-BINDING POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME |
| US6287787B1 (en) | 1993-11-24 | 2001-09-11 | Torrey Pines Institute For Molecular Studies | Dimeric oligopeptide mixture sets |
| AU1967495A (en) | 1994-02-18 | 1995-09-04 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5506207A (en) | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| US5824483A (en) | 1994-05-18 | 1998-10-20 | Pence Inc. | Conformationally-restricted combinatiorial library composition and method |
| JP3166482B2 (ja) | 1994-06-07 | 2001-05-14 | 日産自動車株式会社 | 反射干渉作用を有する発色構造体 |
| US6407059B1 (en) | 1994-06-08 | 2002-06-18 | Peptor Limited | Conformationally constrained backbone cyclized peptide analogs |
| IL109943A (en) | 1994-06-08 | 2006-08-01 | Develogen Israel Ltd | Conformationally constrained backbone cyclized peptide analogs |
| US7553929B2 (en) | 1994-06-13 | 2009-06-30 | Vanderbilt University | Cell permeable peptides for inhibition of inflammatory reactions and methods of use |
| US5807746A (en) | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
| US5702908A (en) | 1994-07-20 | 1997-12-30 | University Of Dundee | Interruption of binding of MDM2 and p53 protein and therapeutic application thereof |
| US5770377A (en) | 1994-07-20 | 1998-06-23 | University Of Dundee | Interruption of binding of MDM2 and P53 protein and therapeutic application thereof |
| BR9508959A (pt) | 1994-09-19 | 1997-12-30 | Ricardo J Moro | "Detecção e tratamento de cancer" |
| CA2158782C (en) | 1994-09-23 | 2010-01-12 | Pierrette Gaudreau | Marker for growth hormone-releasing factor receptors |
| US5681928A (en) | 1994-12-16 | 1997-10-28 | The Salk Institute For Biological Studies | Betides and methods for screening peptides using same |
| ATE544776T1 (de) | 1994-12-29 | 2012-02-15 | Massachusetts Inst Technology | Chimäre dna-bindeproteine |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| US6169073B1 (en) | 1995-02-16 | 2001-01-02 | Bayer Corporation | Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function |
| EP0729972A1 (de) | 1995-02-28 | 1996-09-04 | F. Hoffmann-La Roche Ag | Tetrahydronaphthalin-Peptidderivate |
| US5675001A (en) | 1995-03-14 | 1997-10-07 | Hoffman/Barrett, L.L.C. | Heteroatom-functionalized porphyrazines and multimetallic complexes and polymers derived therefrom |
| US6514942B1 (en) | 1995-03-14 | 2003-02-04 | The Board Of Regents, The University Of Texas System | Methods and compositions for stimulating T-lymphocytes |
| US5700775A (en) | 1995-03-24 | 1997-12-23 | Gutniak; Mark K. | Method and treatment composition for decreasing patient time in catabolic state after traumatic injury |
| US6090958A (en) | 1995-03-31 | 2000-07-18 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| BR9604880A (pt) | 1995-03-31 | 1998-05-19 | Emisphere Tech Inc | Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| US6054556A (en) | 1995-04-10 | 2000-04-25 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Melanocortin receptor antagonists and agonists |
| US5731408A (en) | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
| JPH11503454A (ja) | 1995-04-14 | 1999-03-26 | ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド | 成長ホルモン放出因子の類似体 |
| US5672584A (en) | 1995-04-25 | 1997-09-30 | The University Of Kansas | Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability |
| US6184344B1 (en) | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
| PT832096E (pt) | 1995-05-04 | 2002-01-30 | Scripps Research Inst | Sintese de proteinas atraves de ligacao quimica nativa |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| US6020311A (en) | 1995-05-26 | 2000-02-01 | Theratechnologies, Inc. | GRF analogs with increased biological potency |
| EP0828758B1 (en) | 1995-05-26 | 2001-08-29 | Theratechnologies Inc. | Chimeric fatty body-pro-grf analogs with increased biological potency |
| US6458764B1 (en) | 1995-05-26 | 2002-10-01 | Theratechnologies Inc. | GRF analogs with increased biological potency |
| US5817789A (en) | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
| US6413994B1 (en) | 1999-02-22 | 2002-07-02 | The Salk Institute For Biological Studies | Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
| US6051554A (en) | 1995-06-07 | 2000-04-18 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
| US5811515A (en) | 1995-06-12 | 1998-09-22 | California Institute Of Technology | Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis |
| FR2738151B1 (fr) | 1995-09-04 | 1997-09-26 | Rhone Poulenc Rorer Sa | Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers |
| EP0766966A3 (en) | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
| US5750499A (en) | 1995-10-18 | 1998-05-12 | The Salk Institute For Biological Studies | Receptor-selective somatostatin analogs |
| GB9521544D0 (en) | 1995-10-20 | 1995-12-20 | Univ Dundee | Activation of P53 protein and therapeutic applications thereof |
| US6123964A (en) | 1995-10-27 | 2000-09-26 | Merck & Co., Inc. | Wet granulation formulation of a growth hormone secretagogue |
| US5840833A (en) | 1995-10-27 | 1998-11-24 | Molecumetics, Ltd | Alpha-helix mimetics and methods relating thereto |
| PL327227A1 (en) | 1995-12-22 | 1998-12-07 | Novo Nordisk As | Compounds exhibiting growth hormone liberating properties |
| US5807983A (en) | 1995-12-28 | 1998-09-15 | The Salk Institute For Biological Studies | GNRH antagonist betides |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| US5849954A (en) | 1996-01-18 | 1998-12-15 | Research Corporation Technologies, Inc. | Method of peptide synthesis |
| WO1997026278A1 (en) | 1996-01-18 | 1997-07-24 | Steeno Research Group A/S | Synthetic il-10 analogues |
| US5849691A (en) | 1996-02-20 | 1998-12-15 | The United States Of America As Represented By The Department Of Health And Human Services | Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II |
| AU2595697A (en) | 1996-03-29 | 1997-10-22 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| JP3792777B2 (ja) | 1996-05-10 | 2006-07-05 | 株式会社カネカ | １−アルコキシカルボニル−３−フェニルプロピル誘導体の製造方法 |
| AU3220097A (en) | 1996-05-22 | 1997-12-09 | Arch Development Corporation | Sleep quality improvement using a growth hormone secretagogue |
| US5817752A (en) | 1996-06-06 | 1998-10-06 | La Jolla Pharmaceutical Company | Cyclic polypeptides comprising a thioether linkage and methods for their preparation |
| ES2136458T3 (es) | 1996-06-14 | 1999-11-16 | Takeda Chemical Industries Ltd | Metodo para separar la metionina n-terminal. |
| US5817627A (en) | 1996-06-14 | 1998-10-06 | Theratechnologies Inc. | Long-acting galenical formulation for GRF peptides |
| US5663316A (en) | 1996-06-18 | 1997-09-02 | Clontech Laboratories, Inc. | BBC6 gene for regulation of cell death |
| EP0958305B1 (en) | 1996-07-05 | 2008-06-04 | Cancer Research Technology Limited | Inhibitions of the interaction between p53 and mdm2 |
| US7083983B2 (en) | 1996-07-05 | 2006-08-01 | Cancer Research Campaign Technology Limited | Inhibitors of the interaction between P53 and MDM2 |
| DE69734215T2 (de) | 1996-07-22 | 2006-06-29 | Novo Nordisk A/S | Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften |
| US5955593A (en) | 1996-09-09 | 1999-09-21 | Washington University | BH3 interacting domain death agonist |
| US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
| US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
| GB9619757D0 (en) | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
| US5856445A (en) | 1996-10-18 | 1999-01-05 | Washington University | Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator |
| JP4024309B2 (ja) | 1996-10-22 | 2007-12-19 | 第一三共株式会社 | 新規な感染症治療薬 |
| US6271198B1 (en) | 1996-11-06 | 2001-08-07 | Genentech, Inc. | Constrained helical peptides and methods of making same |
| EP0948343B1 (en) | 1996-11-21 | 2006-02-08 | Promega Corporation | Alkyl peptide amides adapted for topical administration |
| CZ290347B6 (cs) | 1997-02-07 | 2002-07-17 | Ústav organické chemie a biochemie AV ČR | Cyklopeptidy stimulující uvolňování růstového hormonu a způsob jejich přípravy |
| US6313088B1 (en) | 1997-02-07 | 2001-11-06 | Emisphere Technologies, Inc. | 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents |
| US6060513A (en) | 1997-02-07 | 2000-05-09 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| BR9807456A (pt) | 1997-02-20 | 2000-04-25 | Yeda Res & Dev | Peptìdios antipatogênicos sintéticos e composições que compreendem os mesmos |
| US6849428B1 (en) | 1997-03-05 | 2005-02-01 | New England Biolabs, Inc. | Intein-mediated protein ligation of expressed proteins |
| US6635740B1 (en) | 1997-03-27 | 2003-10-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Ligand/lytic peptide compositions and methods of use |
| AU6895598A (en) | 1997-04-11 | 1998-11-11 | Eli Lilly And Company | Combinatorial libraries of peptidomimetic macrocycles and processes therefor |
| GB9708092D0 (en) | 1997-04-22 | 1997-06-11 | Univ Dundee | Materials and methods relating to inhibiting the interaction of p53 and mdm2 |
| US6329368B1 (en) | 1997-05-09 | 2001-12-11 | The Regents Of The University Of California | Endocrine modulation with positive modulators of AMPA type glutamate receptors |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| US6127341A (en) | 1997-06-20 | 2000-10-03 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
| CA2304124A1 (en) | 1997-09-17 | 1999-03-25 | The Walter And Eliza Hall Institute Of Medical Research | Bci-2-like protein bim and methods of use thereof |
| AU9565598A (en) | 1997-09-26 | 1999-04-23 | Board Of Trustees Of The University Of Illinois, The | Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis |
| US6165732A (en) | 1997-10-14 | 2000-12-26 | Washington University | Method for identifying apoptosis modulating compounds |
| US6875594B2 (en) | 1997-11-13 | 2005-04-05 | The Rockefeller University | Methods of ligating expressed proteins |
| US6177076B1 (en) | 1997-12-09 | 2001-01-23 | Thomas Jefferson University | Method of treating bladder cancer with wild type vaccinia virus |
| WO1999034833A1 (en) | 1998-01-07 | 1999-07-15 | Shearwater Polymers, Incorporated | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US6030997A (en) | 1998-01-21 | 2000-02-29 | Eilat; Eran | Acid labile prodrugs |
| CA2318152A1 (en) | 1998-01-29 | 1999-08-05 | Poly-Med Inc. | Absorbable microparticles |
| JP2002501907A (ja) | 1998-01-29 | 2002-01-22 | キナートン・リミテッド | 吸収可能なマイクロ粒子の製造法 |
| AU757658B2 (en) | 1998-03-09 | 2003-02-27 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| AU767185B2 (en) | 1998-03-23 | 2003-11-06 | President And Fellows Of Harvard College | Synthesis of compounds and libraries of compounds |
| EP1093458A4 (en) | 1998-04-15 | 2001-07-18 | Aventis Pharm Prod Inc | METHOD FOR THE PRODUCTION OF RESIN-TIED CYCLIC PEPTIDES |
| US6190699B1 (en) | 1998-05-08 | 2001-02-20 | Nzl Corporation | Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa |
| AU4543899A (en) | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| US6326354B1 (en) | 1998-08-19 | 2001-12-04 | Washington University | Modulation of apoptosis with bid |
| US6194402B1 (en) | 1998-09-02 | 2001-02-27 | Merck & Co., Inc. | Enhancement of return to independent living status with a growth hormone secretagogue |
| US7173005B2 (en) | 1998-09-02 | 2007-02-06 | Antyra Inc. | Insulin and IGF-1 receptor agonists and antagonists |
| US6572856B1 (en) | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
| US6696063B1 (en) | 1998-12-30 | 2004-02-24 | Applied Research Systems Ars Holding N.V. | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
| ATE380548T1 (de) | 1999-01-29 | 2007-12-15 | Univ Illinois | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie |
| US6372490B1 (en) | 1999-02-23 | 2002-04-16 | Curagen Corporation | Nucleic acid encoding the MDM interacting protein |
| WO2000052210A2 (en) | 1999-03-01 | 2000-09-08 | Variagenics, Inc. | Methods for targeting rna molecules |
| DK1165613T3 (da) | 1999-03-29 | 2008-08-25 | Procter & Gamble | Melanocortinreceptorligander |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6713280B1 (en) | 1999-04-07 | 2004-03-30 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
| EP1176880B1 (en) | 1999-04-27 | 2005-06-01 | Aionix Investments Ltd. | Supplement for restoring growth hormone levels |
| US20090175821A1 (en) | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| WO2000071096A2 (en) | 1999-05-24 | 2000-11-30 | Introgen Therapeutics, Inc. | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
| EP1204321B1 (en) | 1999-07-26 | 2005-11-09 | Baylor College Of Medicine | Super-active porcine growth hormone releasing hormone analog |
| US6461634B1 (en) | 1999-08-20 | 2002-10-08 | Edward Marshall | Food-based delivery of HGH-stimulating and other nutritional supplements |
| US20080032931A1 (en) | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
| US20020016298A1 (en) | 1999-09-01 | 2002-02-07 | Hay Bruce A. | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor |
| US6696418B1 (en) | 1999-09-01 | 2004-02-24 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
| US20030181367A1 (en) | 1999-09-27 | 2003-09-25 | O'mahony Daniel | Conjugates of membrane translocating agents and pharmaceutically active agents |
| CA2392019A1 (en) | 1999-11-22 | 2001-05-31 | Zymogenetics, Inc. | Method of forming a peptide-receptor complex with zsig33 |
| US6831155B2 (en) | 1999-12-08 | 2004-12-14 | President And Fellows Of Harvard College | Inhibition of p53 degradation |
| US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
| US6579967B1 (en) | 1999-12-14 | 2003-06-17 | The Salk Institute For Biological Studies | Receptor-selective somatostatin analogs |
| ATE319996T1 (de) | 1999-12-16 | 2006-03-15 | Chugai Pharmaceutical Co Ltd | Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| DE10009341A1 (de) | 2000-02-22 | 2001-09-06 | Florian Kern | Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten |
| US6495674B1 (en) | 2000-02-25 | 2002-12-17 | The Salk Institute For Biological Studies | Evectins and their use |
| US20020002198A1 (en) | 2000-04-17 | 2002-01-03 | Parr Tyler B. | Chemical synergy to elevate growth hormone release in vertebrates |
| US6495589B2 (en) | 2000-04-28 | 2002-12-17 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
| US6897286B2 (en) | 2000-05-11 | 2005-05-24 | Zymogenetics, Inc. | Zsig33-like peptides |
| US20020061838A1 (en) | 2000-05-17 | 2002-05-23 | Barton Holmquist | Peptide pharmaceutical formulations |
| ATE446758T1 (de) | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts |
| IL143690A0 (en) | 2000-06-19 | 2002-04-21 | Pfizer Prod Inc | The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
| IL143942A0 (en) | 2000-06-29 | 2002-04-21 | Pfizer Prod Inc | Use of growth hormone secretagogues for treatment of physical performance decline |
| US7166712B2 (en) | 2000-07-12 | 2007-01-23 | Philadelphia, Health And Education Corporation | Mammalian MDM2 binding proteins and uses thereof |
| IL144468A0 (en) | 2000-07-27 | 2002-05-23 | Pfizer Prod Inc | Use of growth hormone secretagogues for improvement of functional health status |
| US7049290B2 (en) | 2000-07-28 | 2006-05-23 | Universität Zürich | Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon |
| EP1305338A2 (en) | 2000-08-02 | 2003-05-02 | Theratechnologies Inc. | Modified peptides with increased potency |
| US20040228866A1 (en) | 2000-08-04 | 2004-11-18 | Ludwig Institute For Cancer Research | Suppressor genes |
| AU2001284942A1 (en) | 2000-08-16 | 2002-02-25 | Georgetown University Medical Center | Small molecule inhibitors targeted at bcl-2 |
| MXPA03001771A (es) | 2000-08-30 | 2003-06-04 | Pfizer Prod Inc | Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento. |
| IL145106A0 (en) | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| ATE500838T1 (de) | 2000-09-08 | 2011-03-15 | Amylin Pharmaceuticals Inc | ßPSEUDOß-NATIVE CHEMISCHE LIGATION |
| US6720330B2 (en) | 2000-11-17 | 2004-04-13 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
| US20030074679A1 (en) | 2000-12-12 | 2003-04-17 | Schwartz Robert J. | Administration of nucleic acid sequence to female animal to enhance growth in offspring |
| CA2432111A1 (en) | 2000-12-19 | 2002-08-22 | The Johns Hopkins University | Jfy1 protein induces rapid apoptosis |
| US20020091090A1 (en) | 2000-12-28 | 2002-07-11 | Cole Bridget M. | Somatostatin antagonists and agonists |
| CU23157A1 (es) | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL |
| CN1491233A (zh) | 2001-02-02 | 2004-04-21 | 康久化学公司 | 长效生长激素释放因子衍生物 |
| BRPI0207502B1 (pt) | 2001-02-23 | 2018-10-09 | Polyphor Ltd | compostos, enanciômeros, composição farmacêutica, uso de compostos, e, processo para a fabricação de compostos |
| GB0104588D0 (en) | 2001-02-24 | 2001-04-11 | Univ Dundee | Novel p-53 inducible protein |
| DE10109813A1 (de) | 2001-03-01 | 2002-09-12 | Thomas Stanislawski | Tumor-Peptidantigen aus humanem mdm2 Proto-Onkogen |
| US20050054770A1 (en) | 2001-03-09 | 2005-03-10 | Spatola Arno F. | Helicomimetics and stabilized lxxll peptidomimetics |
| US7019109B2 (en) | 2001-03-16 | 2006-03-28 | The Salk Institute For Bilogical Studies | SSTR1-selective analogs |
| JP2004531520A (ja) | 2001-04-09 | 2004-10-14 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | ソマトスタチンアゴニスト |
| US6368617B1 (en) | 2001-05-15 | 2002-04-09 | Reliv' International, Inc. | Dietary supplement |
| PT1392441E (pt) | 2001-06-05 | 2008-09-30 | Elan Pharma Int Ltd | Sistema e método para trituração de materiais |
| EP1411924A1 (en) | 2001-07-06 | 2004-04-28 | Auckland Uniservices Limited | Hypertension treatment |
| US20050245764A1 (en) | 2001-08-08 | 2005-11-03 | Koki Yamashita | Process for producing optically active 2-substituted carboxylic acid |
| AU2002324909A1 (en) | 2001-09-07 | 2003-03-24 | Baylor College Of Medicine | Linear dna fragments for gene expression |
| US20040106548A1 (en) | 2001-09-07 | 2004-06-03 | Schmidt Michelle A | Conformationally constrained labeled peptides for imaging and therapy |
| US20020045192A1 (en) | 2001-09-19 | 2002-04-18 | St. Jude Children's Research Hospital | Arf and HDM2 interaction domains and methods of use thereof |
| EP1312363A1 (en) | 2001-09-28 | 2003-05-21 | Pfizer Products Inc. | Methods of treatment and kits comprising a growth hormone secretagogue |
| US20030083241A1 (en) | 2001-11-01 | 2003-05-01 | Young Charles W. | Use of somatostatin receptor agonists in the treatment of human disorders of sleep hypoxia and oxygen deprivation |
| CN101157924A (zh) | 2001-12-11 | 2008-04-09 | 人体基因组科学有限公司 | 嗜中性白细胞因子α |
| EP1321474A1 (en) | 2001-12-18 | 2003-06-25 | Universite De Geneve | A method for inducing apoptosis |
| US7485620B2 (en) | 2001-12-18 | 2009-02-03 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| WO2003055510A1 (en) | 2001-12-24 | 2003-07-10 | Auckland Uniservices Limited | Therapy for growth hormone induced insulin resistance in juveniles with growth disorders |
| CA2471719A1 (en) | 2001-12-31 | 2003-07-17 | Dana-Farber Cancer Institute, Inc. | Method of treating apoptosis and compositions thereof |
| EP1468013A4 (en) | 2002-01-03 | 2005-03-16 | Yissum Res Dev Co | CYCLIC PEPTIDES WITH CARBON SKELETON HAVING RESTRICTED CONFORMATION |
| US20040230380A1 (en) | 2002-01-04 | 2004-11-18 | Xencor | Novel proteins with altered immunogenicity |
| NZ534935A (en) | 2002-02-07 | 2010-04-30 | Baylor College Medicine | Modified pituitary gland development in offspring from expectant mother animals treated with gene therapy involving growth hormone releasing hormone therapy |
| EP1476178A4 (en) | 2002-02-14 | 2009-08-26 | Bayer Pharmaceuticals Corp | FORMULATION STRATEGIES IN STABILIZING PEPTIDES IN ORGANIC SOLVENTS AND DRY CONDITIONS |
| AU2003211093A1 (en) | 2002-02-15 | 2003-09-09 | The Regents Of The University Of Michigan | Inhibitors of rgs proteins |
| US20030166138A1 (en) | 2002-02-21 | 2003-09-04 | Todd Kinsella | Cyclic peptides and analogs useful to treat allergies |
| AU2003227066A1 (en) | 2002-03-26 | 2003-10-08 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs) |
| US7498134B2 (en) | 2002-03-30 | 2009-03-03 | The Trustees Of Columbia University In The City Of New York | HAUSP-Mdm2 interaction and uses thereof |
| DE60320780D1 (de) | 2002-04-22 | 2008-06-19 | Univ Florida | Funktionalisierte nanopartikel und verwendungsverfahren |
| AU2003235504A1 (en) | 2002-05-13 | 2003-11-11 | 3-Dimensional Pharmaceuticals, Inc. | Method for cytoprotection through mdm2 and hdm2 inhibition |
| WO2003102538A2 (en) | 2002-05-30 | 2003-12-11 | European Molecular Biology Laboratory | Combinatorial chemical library ii |
| WO2003101972A1 (en) | 2002-05-30 | 2003-12-11 | The Scripps Research Institute | Copper-catalysed ligation of azides and acetylenes |
| US7208154B2 (en) | 2002-06-03 | 2007-04-24 | Regents Of The University Of Michigan | Methods and compositions for the treatment of MHC-associated conditions |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| AU2003253883A1 (en) | 2002-07-15 | 2004-02-02 | The Johns Hopkins University | Neuronal and optic nerve gene expression patterns |
| WO2004009614A2 (en) | 2002-07-24 | 2004-01-29 | The Salk Institute For Biological Studies | Receptor (sstr4)- selective somatostatin analogs |
| US20060051846A1 (en) | 2002-09-06 | 2006-03-09 | Kaneka Corporation | Process for producing l-alpha-methylcysteine derivative |
| AU2003267124A1 (en) | 2002-09-09 | 2004-03-29 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| US20060128615A1 (en) | 2002-09-18 | 2006-06-15 | Pierrette Gaudreau | Ghrh analogues |
| AU2003277891A1 (en) | 2002-09-23 | 2004-04-08 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
| CA2487206A1 (en) | 2002-10-07 | 2004-04-15 | Ludwig Institute Cancer Research | P53 binding polypeptide |
| US20040208866A1 (en) | 2002-10-07 | 2004-10-21 | Jaspers Stephen R. | Methods of regulating body weight |
| EP1407779A1 (en) | 2002-10-10 | 2004-04-14 | Gastrotech A/S | Use of ghrelin for treating low body weight and body fat in gastrectomized individuals |
| DK1562941T3 (da) | 2002-11-07 | 2010-04-19 | Kosan Biosciences Inc | Trans-9,10-dehydroepothilon C og D, analoger deraf og fremstillingsmåder til fremstilling heraf |
| ES2295692T3 (es) | 2002-11-08 | 2008-04-16 | F. Hoffmann-La Roche Ag | Nuevos derivados de 4-alcoxioxazol sustituido como agonistas de ppar. |
| US20050227932A1 (en) | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| EP1578798A1 (en) | 2002-12-20 | 2005-09-28 | 7TM Pharma A/S | Ghrelin receptor inverse agonist for regulation of feeding behaviours |
| WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| WO2004067719A2 (en) | 2003-01-28 | 2004-08-12 | Advisys, Inc. | Growth hormone releasing hormone (ghrh) for use in reducing culling in herd animals |
| US20050059605A1 (en) | 2003-01-31 | 2005-03-17 | Krishna Peri | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| EP1609802A4 (en) | 2003-02-26 | 2006-06-21 | Japan Science & Tech Agency | TRANSCRIPTIONAL FACTOR INDUCING APOPTOSIS IN CANCER CELLS |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| US20070060512A1 (en) | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
| WO2004084943A1 (en) | 2003-03-19 | 2004-10-07 | Beth Israel Deaconess Medical Center, Inc | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation |
| US7632920B2 (en) | 2003-04-10 | 2009-12-15 | Schering Corporation | Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof |
| CN100506841C (zh) | 2003-05-01 | 2009-07-01 | 科内尔研究基金会 | 将分子递送到细胞的方法和载体复合物 |
| CN1822851B (zh) | 2003-05-15 | 2011-04-13 | 塔夫茨大学信托人 | 肽和多肽药物的稳定类似物 |
| AU2003229222B2 (en) | 2003-05-29 | 2009-11-12 | Theratechnologies Inc. | GRF analog compositions and their use |
| AU2003902743A0 (en) | 2003-06-02 | 2003-06-19 | Promics Pty Limited | Process for the preparation of cyclic peptides |
| EP1643970A2 (en) | 2003-06-09 | 2006-04-12 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of growth hormone |
| USRE42013E1 (en) | 2003-06-18 | 2010-12-28 | Tranzyme Pharma Inc. | Macrocyclic modulators of the ghrelin receptor |
| USRE42624E1 (en) | 2003-06-18 | 2011-08-16 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| CA2528375C (en) | 2003-06-18 | 2013-11-19 | Tranzyme Pharma, Inc. | Macrocyclic antagonists of the motilin receptor |
| US20090198050A1 (en) | 2003-06-18 | 2009-08-06 | Tranzyme Pharma Inc. | Macrocyclic Modulators of the Ghrelin Receptor |
| US7491695B2 (en) | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
| WO2005000876A2 (en) | 2003-06-27 | 2005-01-06 | Proteologics, Inc. | Ring finger family proteins and uses related thereto |
| WO2005007675A2 (en) | 2003-07-09 | 2005-01-27 | The Scripps Research Institute | TRIAZOLE ϵ-AMINO ACIDS |
| GB0317815D0 (en) | 2003-07-30 | 2003-09-03 | Amersham Health As | Imaging agents |
| US7695426B2 (en) | 2003-08-20 | 2010-04-13 | Biological Resources Pty Ltd | Methods for enhancing viability |
| CN100475271C (zh) | 2003-08-20 | 2009-04-08 | 加利福尼亚大学董事会 | 具有抑制生长激素释放活性的促生长素抑制素类似物 |
| WO2005027913A1 (en) | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
| US9408405B2 (en) | 2003-10-03 | 2016-08-09 | Veijlen N.V. | Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals |
| AU2004277981B2 (en) | 2003-10-03 | 2009-10-01 | Merck & Co., Inc. | Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease |
| WO2005040202A2 (en) * | 2003-10-16 | 2005-05-06 | Aplagen Gmbh | Stabilized alpha-helical peptides |
| US20070274915A1 (en) | 2003-10-17 | 2007-11-29 | Anjana Rao | Modulation Of Anergy And Methods For isolating Anergy-Modulating Compounds |
| AU2004281084B2 (en) | 2003-10-20 | 2010-08-12 | Theratechnologies Inc. | Use of growth hormone releasing factor analogs in treating patients suffering from wasting |
| US7273927B2 (en) | 2003-11-03 | 2007-09-25 | University Of Massachusetts | Mdm2 splice variants |
| US20050147581A1 (en) | 2003-11-19 | 2005-07-07 | The Board Of Trustees Of The University Of Illinois | Macromolecular drug complexes having improved stability and therapeutic use of the same |
| US7772367B2 (en) | 2004-01-30 | 2010-08-10 | The Trustees Of Columbia University In The City Of New York | C-terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof |
| US20070161551A1 (en) | 2004-02-10 | 2007-07-12 | De Luca Giampiero | Methods and compositions for the treatment of lipodystrophy |
| GB0404731D0 (en) | 2004-03-03 | 2004-04-07 | Indp Administrative Inst Nims | Method and products for the selective degradation of proteins |
| US20050203009A1 (en) | 2004-03-12 | 2005-09-15 | Bayer Pharmaceuticals Corporation | VPAC1 selective antagonists and their pharmacological methods of use |
| WO2005090388A1 (en) | 2004-03-19 | 2005-09-29 | The University Of Queensland | Alpha helical mimics, their uses and methods for their production |
| EP1735055A1 (en) | 2004-03-30 | 2006-12-27 | Sapphire Therapeutics, Inc. | Method of reducing c-reactive protein using growth hormone secretagogues |
| JP2007532495A (ja) | 2004-04-07 | 2007-11-15 | ガストロテック・ファルマ・アクティーゼルスカブ | グレリン欠乏を治療するための分泌促進薬の使用 |
| US7034050B2 (en) | 2004-04-28 | 2006-04-25 | Romano Deghenghi | Pseudopeptides growth hormone secretagogues |
| EP1753727B1 (en) | 2004-05-18 | 2008-11-19 | F.Hoffmann-La Roche Ag | Novel cis-imidazolines |
| US7202332B2 (en) | 2004-05-27 | 2007-04-10 | New York University | Methods for preparing internally constrained peptides and peptidomimetics |
| CN100335467C (zh) | 2004-06-04 | 2007-09-05 | 中国科学院上海有机化学研究所 | 一锅法区域选择性合成5－碘代－1，4－二取代－1，2，3－三氮唑化合物 |
| US7501397B2 (en) | 2004-06-04 | 2009-03-10 | The Brigham And Women's Hospital, Inc. | Helical peptidomimetics with enhanced activity |
| EP1602663A1 (en) | 2004-06-04 | 2005-12-07 | Chiralix B.V. | Triazole-linked glycoamino acids and glycopeptides |
| US7842815B2 (en) | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| CN102532321B (zh) | 2004-06-18 | 2018-10-12 | Ambrx公司 | 新颖抗原结合多肽和其用途 |
| WO2006010118A2 (en) | 2004-07-09 | 2006-01-26 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
| AU2005272598B2 (en) | 2004-08-12 | 2011-11-17 | Helsinn Therapeutics (U.S.), Inc. | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues |
| JP2008510706A (ja) | 2004-08-18 | 2008-04-10 | エリクシアー ファーマシューティカルズ， インコーポレイテッド | 成長ホルモン分泌促進物質 |
| US7151084B2 (en) | 2004-12-27 | 2006-12-19 | Miller Landon C G | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes |
| US7157421B2 (en) | 2004-12-27 | 2007-01-02 | Miller Landon C G | Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders |
| US7074775B2 (en) | 2004-09-14 | 2006-07-11 | Miller Landon C G | Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders |
| US7402652B2 (en) | 2004-09-14 | 2008-07-22 | Miller Landon C G | Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders |
| US9598470B2 (en) | 2004-10-07 | 2017-03-21 | Craig W. Beattie | Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways |
| WO2006050034A1 (en) | 2004-10-29 | 2006-05-11 | Schering Corporation | Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| WO2006069001A2 (en) | 2004-12-20 | 2006-06-29 | Baylor College Of Medicine | Structural requirements for stat3 binding and recruitment to phosphototyrosine ligands |
| GB0428187D0 (en) | 2004-12-23 | 2005-01-26 | Univ Liverpool | Cancer treatment |
| PT1844337E (pt) | 2005-01-24 | 2014-04-03 | Pepscan Systems Bv | Compostos ligantes, compostos imunogénicos e peptidomiméticos |
| FR2881430B1 (fr) | 2005-02-01 | 2010-10-22 | Servier Lab | Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations |
| NZ561215A (en) | 2005-02-22 | 2010-12-24 | Univ Michigan | Small molecule inhibitors of MDM2 and uses thereof |
| WO2006103666A2 (en) | 2005-03-28 | 2006-10-05 | Yeda Research And Development Co. Ltd. | Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis |
| WO2006122931A1 (en) | 2005-05-20 | 2006-11-23 | Biovitrum Ab (Publ) | Beta-carboline derivatives and theri use as ghsr modulators |
| EP1891090A2 (en) | 2005-06-13 | 2008-02-27 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
| US20070020620A1 (en) | 2005-07-14 | 2007-01-25 | Finn M G | Compositions and methods for coupling a plurality of compounds to a scaffold |
| EP1909854A4 (en) | 2005-07-21 | 2012-02-22 | Barry John Allen | METHOD FOR TREATING CANCER |
| EP1919492B1 (en) | 2005-07-22 | 2013-03-06 | Ipsen Pharma | Growth hormone secretagogues |
| EP1757290A1 (en) | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
| WO2007038678A2 (en) | 2005-09-28 | 2007-04-05 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Analogs of ghrelin |
| US20070161544A1 (en) | 2006-01-06 | 2007-07-12 | Peter Wipf | Selective targeting agents for mitcochondria |
| US7745573B2 (en) | 2006-02-17 | 2010-06-29 | Polychip Pharmaceuticals Pty Ltd. | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides |
| US7538190B2 (en) | 2006-02-17 | 2009-05-26 | Polychip Pharmaceuticals Pty Ltd | Methods for the synthesis of two or more dicarba bridges in organic compounds |
| US7981860B2 (en) | 2006-03-13 | 2011-07-19 | Liat Mintz | Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation |
| US8536120B2 (en) | 2006-04-28 | 2013-09-17 | The Administrators Of The Tulane Educational Fund | Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof |
| GB0611405D0 (en) | 2006-06-09 | 2006-07-19 | Univ Belfast | FKBP-L: A novel inhibitor of angiogenesis |
| US7425542B2 (en) | 2006-06-23 | 2008-09-16 | Aegis Therapeutics, Inc. | Stabilizing alkylglycoside compositions and methods thereof |
| JP2009542664A (ja) | 2006-06-30 | 2009-12-03 | シェーリング コーポレイション | Ｐ５３活性を増大させる置換されたピペリジンの使用の方法 |
| CA2656398A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| AU2007272954A1 (en) | 2006-07-11 | 2008-01-17 | Harkness Pharmaceuticals, Inc. | Methods of treating obesity using satiety factors |
| US8614192B2 (en) | 2006-07-28 | 2013-12-24 | Leiden University Medical Center | Method for treating ocular cancer |
| US7737174B2 (en) | 2006-08-30 | 2010-06-15 | The Regents Of The University Of Michigan | Indole inhibitors of MDM2 and the uses thereof |
| DE602007010664D1 (de) | 2006-09-04 | 2010-12-30 | Univ Dundee | P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen |
| WO2008033557A2 (en) | 2006-09-15 | 2008-03-20 | Siemens Medical Solutions Usa, Inc. | Click chemistry-derived cyclic peptidomimetics as integrin markers |
| US7897394B2 (en) | 2006-09-21 | 2011-03-01 | Intrexon Corporation | Endoplasmic reticulum localization signals |
| CN101516366B (zh) | 2006-09-21 | 2012-05-30 | 霍夫曼-拉罗奇有限公司 | 作为抗癌剂的羟吲哚衍生物 |
| WO2008040000A2 (en) | 2006-09-28 | 2008-04-03 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| US8940864B2 (en) | 2006-10-05 | 2015-01-27 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| US8691761B2 (en) | 2006-10-16 | 2014-04-08 | Jean E. F. Rivier | Somatostatin receptor 2 antagonists |
| PL2383289T3 (pl) | 2006-10-16 | 2015-03-31 | Salk Inst Biological Studies | Antagoniści somatostatyny selektywni względem receptora (SSTR2) |
| JP2010510236A (ja) | 2006-11-15 | 2010-04-02 | ダナ−ファーバー キャンサー インスティテュート インク． | 安定化させたｍａｍｌペプチドおよびその使用法 |
| US7932397B2 (en) | 2006-11-22 | 2011-04-26 | Massachusetts Institute Of Technology | Olefin metathesis catalysts and related methods |
| BRPI0720306A2 (pt) | 2006-12-14 | 2014-02-04 | Aileron Therapeutics Inc | Sistemas de macrociclização da bis-sufidrila |
| US7981998B2 (en) | 2006-12-14 | 2011-07-19 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
| AU2007345497B2 (en) | 2007-01-29 | 2013-01-17 | Polyphor Ltd. | Template-fixed peptidomimetics |
| PL2118123T3 (pl) | 2007-01-31 | 2016-06-30 | Dana Farber Cancer Inst Inc | Stabilizowane peptydy p53 i ich zastosowania |
| CA2677399C (en) | 2007-02-09 | 2016-09-13 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
| CA2678941C (en) | 2007-02-23 | 2018-11-27 | Aileron Therapeutics, Inc. | Triazole macrocycle systems |
| WO2008106507A2 (en) | 2007-02-27 | 2008-09-04 | University Of South Florida | Mdm2/mdmx inhibitor peptide |
| US8618324B2 (en) | 2007-03-13 | 2013-12-31 | Board Of Regents, The University Of Texas System | Composition and method for making oligo-benzamide compounds |
| JP5631201B2 (ja) | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ステッチングされたポリペプチド |
| TWI429436B (zh) | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
| US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| EP2150537A4 (en) | 2007-06-01 | 2010-09-22 | Acologix Inc | STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE |
| ATE547415T1 (de) | 2007-09-21 | 2012-03-15 | Janssen Pharmaceutica Nv | Inhibitoren der wechselwirkung zwischen mdm2 und p53 |
| WO2009042237A2 (en) | 2007-09-26 | 2009-04-02 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| BRPI0906685A2 (pt) | 2008-01-25 | 2016-10-11 | Massachusetts Inst Technology | catalisadores para reações de metátese incluindo metátese de olefina enantiosseletiva, e métodos relacionados |
| CN104474529A (zh) | 2008-02-08 | 2015-04-01 | 爱勒让治疗公司 | 治疗性的拟肽大环化合物 |
| US20110144303A1 (en) | 2008-04-08 | 2011-06-16 | Aileron Therapeutics, Inc. | Biologically Active Peptidomimetic Macrocycles |
| WO2009126292A2 (en) | 2008-04-08 | 2009-10-15 | Aileron Therapeutics, Inc. | Biologically active peptidomimetic macrocycles |
| CA2725227A1 (en) | 2008-05-06 | 2009-11-12 | Asim Kumar Debnath | Antiviral cell penetrating peptides |
| WO2009149339A2 (en) | 2008-06-05 | 2009-12-10 | University Of Maryland, Baltimore | P53 activator peptides |
| US20110144306A1 (en) | 2008-07-23 | 2011-06-16 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
| GB0813873D0 (en) | 2008-07-30 | 2008-09-03 | Univ Dundee | Compounds |
| US8586707B2 (en) | 2008-09-16 | 2013-11-19 | The Research Foundation Of State University Of New York | Stapled peptides and method of synthesis |
| CN104961795A (zh) | 2008-09-22 | 2015-10-07 | 爱勒让治疗公司 | 用于制备纯化的多肽组合物的方法 |
| CN102482336B (zh) | 2008-09-22 | 2015-05-06 | 爱勒让治疗公司 | 拟肽大环化合物 |
| US20110218155A1 (en) | 2008-10-10 | 2011-09-08 | Dana-Farber Cancer Institute, Inc. | Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides |
| JP2010120881A (ja) | 2008-11-19 | 2010-06-03 | Keio Gijuku | ヒト癌タンパク質ＭＤＭ２とヒト癌抑制タンパク質ｐ５３との相互作用阻害ペプチド及びその使用 |
| KR101298168B1 (ko) | 2008-11-21 | 2013-08-20 | 충남대학교산학협력단 | 스네일―ｐ５３ 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제 |
| CA2743177A1 (en) | 2008-11-24 | 2010-05-27 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with improved properties |
| WO2010083501A2 (en) | 2009-01-16 | 2010-07-22 | University Of South Florida | Alpha-helix mimetic using a 2,5-oligopyrimidine scaffold |
| US8217051B2 (en) | 2009-02-17 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| FR2942798B1 (fr) | 2009-03-05 | 2011-04-08 | Centre Nat Rech Scient | Peptides utilisables pour le traitement de la leucemie lymphoide chronique |
| WO2010107485A1 (en) | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | E3 ligase inhibitors |
| AU2010239125B2 (en) | 2009-04-22 | 2015-05-14 | The Walter And Eliza Hall Institute Of Medical Research | Structure of the C-terminal region of the insulin receptor alpha-chain and of the insulin-like growth factor receptor alpha-chain |
| US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| WO2011005219A1 (en) | 2009-07-07 | 2011-01-13 | Agency For Science, Technology And Research | Novel mdm2 binding peptides and uses thereof |
| BR112012000867A2 (pt) | 2009-07-13 | 2019-09-24 | Harvard College | "polipeptídeos bifuncional costurado e uso do mesmo" |
| AU2010288534A1 (en) | 2009-08-26 | 2012-03-15 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators |
| JP2013505300A (ja) | 2009-09-22 | 2013-02-14 | エルロン・セラピューティクス・インコーポレイテッド | ペプチド模倣大環状分子 |
| US8017607B2 (en) | 2009-10-14 | 2011-09-13 | Hoffmann-La Roche Inc. | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions |
| AU2010306718A1 (en) | 2009-10-14 | 2012-05-24 | Aileron Therapeutics, Inc. | Improved peptidomimetic macrocycles |
| US20120283269A1 (en) | 2009-11-04 | 2012-11-08 | Health Research Inc. | Method and Compositions for Suppression of Aging |
| JP2013510860A (ja) | 2009-11-12 | 2013-03-28 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン | スピロ−オキシインドールｍｄｍ２アンタゴニスト |
| US20110118283A1 (en) | 2009-11-17 | 2011-05-19 | Qingjie Ding | Substituted Pyrrolidine-2-Carboxamides |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| US8658170B2 (en) | 2010-01-06 | 2014-02-25 | Joseph P. Errico | Combination therapy with MDM2 and EFGR inhibitors |
| KR101220516B1 (ko) | 2010-01-21 | 2013-01-10 | 연세대학교 산학협력단 | 항－ｍｄｍ２를 발현하는 인간 성체줄기세포 및 그의 용도 |
| WO2011097642A1 (en) | 2010-02-08 | 2011-08-11 | Trustees Of Boston College | Efficient methods for z- or cis-selective cross-metathesis |
| US8288431B2 (en) | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
| WO2011106650A2 (en) | 2010-02-27 | 2011-09-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease |
| CA2800519A1 (en) | 2010-04-09 | 2011-10-13 | The Regents Of The University Of Michigan | Biomarkers for mdm2 inhibitors for use in treating disease |
| US20110313167A1 (en) | 2010-06-22 | 2011-12-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Substituted Heterocycles as Therapeutic agents for treating cancer |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| US8975232B2 (en) | 2010-07-29 | 2015-03-10 | President And Fellows Of Harvard College | Macrocyclic kinase inhibitors and uses thereof |
| KR102104762B1 (ko) | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| US9187441B2 (en) | 2010-09-08 | 2015-11-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | p53-Mdm2 antagonists |
| US20120065210A1 (en) | 2010-09-15 | 2012-03-15 | Xin-Jie Chu | Substituted hexahydropyrrolo[1,2-c]imidazolones |
| CN102399283B (zh) | 2010-09-17 | 2013-05-29 | 中国农业大学 | 水貂生长激素释放激素cDNA及其应用 |
| CN102399284B (zh) | 2010-09-17 | 2013-05-29 | 中国农业大学 | 狐狸生长激素释放激素cDNA及其应用 |
| US20120071499A1 (en) | 2010-09-20 | 2012-03-22 | Xin-Jie Chu | Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones |
| WO2012040459A2 (en) | 2010-09-22 | 2012-03-29 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
| US20130225603A1 (en) | 2010-09-27 | 2013-08-29 | Serrata Llc | Mdm2 inhibitors for treatment of ocular conditions |
| US9266860B2 (en) | 2010-09-30 | 2016-02-23 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles |
| EP2627662B1 (en) | 2010-10-13 | 2015-09-16 | Bristol-Myers Squibb Company | Methods for preparing macrocycles and macrocycle stabilized peptides |
| FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
| CA2817585A1 (en) | 2010-11-12 | 2012-05-18 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
| JP2014502152A (ja) | 2010-11-12 | 2014-01-30 | ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド | 癌の治療及び診断 |
| WO2012076513A1 (en) | 2010-12-09 | 2012-06-14 | F. Hoffmann-La Roche Ag | 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer |
| US9029332B2 (en) | 2010-12-15 | 2015-05-12 | The Research Foundation For The State University Of New York | Cross-linked peptides and proteins, methods of making same, and uses thereof |
| JP2014507384A (ja) | 2010-12-16 | 2014-03-27 | ロシュ グリクアート アーゲー | Ｍｄｍ２阻害剤とのアフコシル化ｃｄ２０抗体の併用療法 |
| WO2012083181A1 (en) | 2010-12-16 | 2012-06-21 | Indiana University Research And Technology Corporation | Alpha helix mimetics and methods for using |
| EP2684888B1 (en) | 2011-03-09 | 2019-05-15 | Jitsubo Co., Ltd. | Novel cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method |
| DK2684880T3 (en) | 2011-03-10 | 2018-05-22 | Daiichi Sankyo Co Ltd | DISPIROPYRROLIDINE DERIVATIVES |
| AU2012249301A1 (en) | 2011-04-29 | 2013-11-21 | Kinemed, Inc. | Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents |
| WO2012174423A1 (en) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Stabilized polypeptides as regulators of rab gtpase function |
| GB201110390D0 (en) | 2011-06-20 | 2011-08-03 | Medical Res Council | Compounds for use in stabilising p53 mutants |
| US20120328692A1 (en) | 2011-06-24 | 2012-12-27 | University Of Maryland, Baltimore | Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy |
| CN103889437A (zh) | 2011-08-31 | 2014-06-25 | 纽约大学 | 硫醚、醚和烷基胺连接的氢键替代物肽模拟物 |
| US9517252B2 (en) | 2011-09-09 | 2016-12-13 | Agency For Science, Technology And Research | p53 activating peptides |
| AU2012316055B2 (en) | 2011-09-27 | 2016-05-12 | Amgen Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
| EP2768518A4 (en) | 2011-10-18 | 2015-05-27 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES |
| WO2013062923A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| CA2761253A1 (en) | 2011-12-07 | 2013-06-07 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| US9464125B2 (en) | 2012-02-03 | 2016-10-11 | The Trustees Of Princeton University | Engineered potent cytotoxic stapled BH3 peptides |
| RU2642299C2 (ru) * | 2012-02-15 | 2018-01-24 | Эйлерон Терапьютикс, Инк. | P53 пептидомиметические макроциклы |
| WO2014047673A1 (en) | 2012-09-25 | 2014-04-03 | The Walter And Eliza Hall Institute Of Medical Research | Structure of insulin in complex with n- and c-terminal regions of the insulin receptor alpha-chain |
| RS61957B1 (sr) | 2012-09-26 | 2021-07-30 | Harvard College | Uvezani peptidi blokirani prolinom i njihove upotrebe |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
| CA2902856C (en) | 2013-02-28 | 2021-02-16 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| WO2014197821A1 (en) | 2013-06-06 | 2014-12-11 | President And Fellows Of Harvard College | Homeodomain fusion proteins and uses thereof |
| BR112015031277A2 (pt) | 2013-06-14 | 2017-09-19 | Harvard College | Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos |
| EP3027212A1 (en) | 2013-08-02 | 2016-06-08 | Children's Hospital Medical Center | Compositions and methods for treating disease states associated with activated t cells and/or b cells |
| WO2015051030A2 (en) | 2013-10-01 | 2015-04-09 | President And Fellows Of Harvard College | Stabilized polypeptides and uses thereof |
| KR20160100975A (ko) | 2013-12-23 | 2016-08-24 | 노파르티스 아게 | 제약 조합물 |
| CA2931073C (en) | 2013-12-23 | 2021-10-26 | Novartis Ag | Pharmaceutical combinations |
| CA2996685A1 (en) | 2015-09-03 | 2017-03-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| EP3347372A4 (en) | 2015-09-10 | 2019-09-04 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 |
| US20170349638A1 (en) | 2016-03-21 | 2017-12-07 | Aileron Therapeutics, Inc. | Companion diagnostic tool for peptidomimetic macrocycles |
| WO2017205786A1 (en) | 2016-05-27 | 2017-11-30 | Aileron Therapeutics, Inc. | Cell permeable peptidomimetic macrocycles |
| US20170360881A1 (en) | 2016-06-17 | 2017-12-21 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
-
2008
- 2008-01-31 PL PL08728649T patent/PL2118123T3/pl unknown
- 2008-01-31 JP JP2009548441A patent/JP5649825B2/ja active Active
- 2008-01-31 EP EP08728649.8A patent/EP2118123B1/en active Active
- 2008-01-31 PT PT87286498T patent/PT2118123E/pt unknown
- 2008-01-31 EP EP15154235.4A patent/EP2952522B1/en active Active
- 2008-01-31 CA CA2939778A patent/CA2939778C/en active Active
- 2008-01-31 AU AU2008210434A patent/AU2008210434C8/en not_active Ceased
- 2008-01-31 US US12/525,123 patent/US8889632B2/en active Active
- 2008-01-31 ES ES08728649.8T patent/ES2558928T3/es active Active
- 2008-01-31 CA CA2677045A patent/CA2677045C/en active Active
- 2008-01-31 DK DK08728649.8T patent/DK2118123T3/en active
- 2008-01-31 WO PCT/US2008/052580 patent/WO2008095063A1/en not_active Ceased
-
2014
- 2014-07-03 JP JP2014137588A patent/JP2014224121A/ja active Pending
- 2014-09-11 US US14/483,905 patent/US9527896B2/en active Active
-
2016
- 2016-07-25 JP JP2016145368A patent/JP6775344B2/ja active Active
- 2016-11-16 US US15/352,911 patent/US10202431B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005044839A2 (en) * | 2003-11-05 | 2005-05-19 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2952522A1 (en) | 2015-12-09 |
| JP2014224121A (ja) | 2014-12-04 |
| AU2008210434A1 (en) | 2008-08-07 |
| PT2118123E (pt) | 2016-02-10 |
| EP2118123A1 (en) | 2009-11-18 |
| EP2118123B1 (en) | 2015-10-14 |
| US10202431B2 (en) | 2019-02-12 |
| US20170081379A1 (en) | 2017-03-23 |
| US20100168388A1 (en) | 2010-07-01 |
| AU2008210434C1 (en) | 2013-11-14 |
| CA2677045A1 (en) | 2008-08-07 |
| AU2008210434A8 (en) | 2009-12-17 |
| ES2558928T3 (es) | 2016-02-09 |
| AU2008210434C9 (en) | 2013-12-12 |
| US9527896B2 (en) | 2016-12-27 |
| JP2010518017A (ja) | 2010-05-27 |
| US8889632B2 (en) | 2014-11-18 |
| DK2118123T3 (en) | 2016-01-25 |
| EP2952522B1 (en) | 2019-10-30 |
| CA2939778C (en) | 2019-01-29 |
| CA2939778A1 (en) | 2008-08-07 |
| PL2118123T3 (pl) | 2016-06-30 |
| JP2017039701A (ja) | 2017-02-23 |
| JP6775344B2 (ja) | 2020-10-28 |
| WO2008095063A1 (en) | 2008-08-07 |
| EP2118123A4 (en) | 2011-04-20 |
| CA2677045C (en) | 2016-10-18 |
| AU2008210434B2 (en) | 2013-06-20 |
| US20150119551A1 (en) | 2015-04-30 |
| JP5649825B2 (ja) | 2015-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008210434C1 (en) | Stabilized p53 peptides and uses thereof | |
| AU2024200512B2 (en) | Stabilized peptide-mediated targeted protein degradation | |
| AU2011325910B2 (en) | Cancer therapies and diagnostics | |
| US9074009B2 (en) | Stabilized MAML peptides and uses thereof | |
| CA2864120A1 (en) | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | |
| AU2016316842C1 (en) | Peptides binding to BFL-1 | |
| AU2013231104B2 (en) | Stabilized p53 peptides and uses thereof | |
| AU2016210709A1 (en) | Stabilized p53 peptides and uses thereof | |
| AU2014200485A1 (en) | Stabilized maml peptides and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE APPLICANT NAME NAME TO PRESIDENT & FELLOWS OF HARVARD COLLEGE |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND APPLICANT NAME FROM: DANA-FARBER CANCER INSTITUTE, INC.; PRESIDENT & FELLOWS OF HARVARD COLLEGE TO: DANA-FARBER CANCER INSTITUTE, INC.; PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
|
| TH | Corrigenda |
Free format text: IN VOL 23, NO 32, PAGE(S) 9646 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME DANA-FARBER CANCER INSTITUTE, INC.; PRESIDENT AND FELLOWS OF HARVARD COLLEGE, APPLICATION NO. 2008210434, UNDER INID (72) CORRECT THE INVENTORS TO INCLUDE CO-INVENTOR KORSMEYER, STANLEY |
|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 AUG 2013 . |
|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 AUG 2013 . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 AUG 2013 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 AUG 2013 |
|
| SREP | Specification republished | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 OCT 2013 . |
|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 JAN 2014 . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 JAN 2014 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 OCT 2013 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| TH | Corrigenda |
Free format text: IN VOL 28 , NO 10 , PAGE(S) 1333 UNDER THE HEADING AMENDMENTS - AMENDMENTS MADE DELETE ALL REFERENCE TO 2008210434 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 JAN 2014 |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |